ClinicalTrials.gg
CompletedNCT05337540Updated Dec 8, 2025

A Study to Evaluate the Efficacy, Safety and Tolerability of EVI-01 Intra-Articular Injection in Osteoarthritis of the Knee

An interventional study of EVI-01 and Active comparator Synvisc-One in Osteoarthritis and Osteoarthritis, Knee, sponsored by Aptissen SA. Completed at 2 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-08.

Primary conditionOsteoarthritis, KneeRegistry: OsteoarthritisReclassifiedWhy we changed it
Registry
Osteoarthritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoarthritis, Knee
Why
  1. The study's listed conditions name Osteoarthritis, Knee, a narrower term within Osteoarthritis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Aptissen SA · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Osteoarthritis, Knee with a site in Brazil — 12 open to participants now, 12 under way, 2 of them phase 3. Osteoarthritis, Knee · Brazil.

Enrollment
15th of 77
120 · median 66
Started
2024
with 6 others
No phase
50 of 79
9 open now
Registered
62nd of 79
by date

Among the 79 studies in Osteoarthritis, Knee with a site in Brazil, this one is the 15th largest by enrollment of the 77 interventional ones that give a count, is one of 7 that started in 2024, is one of 50 with no phase, and was the 62nd registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

12 of the 79 studies in Osteoarthritis, Knee with a site in Brazil are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Osteoarthritis, Knee with a site in Brazil, or all of them as a file.
02

Study summary

Objective: Identifying the dose of EVI-01 with the best clinical response, balancing the efficacy, safety, and tolerability of the investigational product.

Study design: Interventional, dose-finding, three arms, randomized (1:1:1), parallel assignment, double-blind, controlled by an active comparator.

Read the detailed description

Phase II, dose-finding, interventional, three-arm, randomized (1:1:1), double-blind, parallel, active-comparator-controlled clinical trial.

03

Conditions studied

  • Osteoarthritis
  • Osteoarthritis, Knee

Browse trials for

04

In context

Osteoarthritis, Knee Reclassified

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's enrollment of 120 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Aptissen SA is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Compared within Osteoarthritis, Knee, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of both genders aged 18 years or older;
  2. (BMI) \< 35 kg/m2;
  3. Diagnosis of primary knee osteoarthritis, Kellgren-Lawrence Grade 2 to 4, according to American College of Rheumatology (ACR) criteria and confirmed radiologically within the previous 12 months, for which an intraarticular treatment is indicated;
  4. Moderate to severe pain measured by VAS (0-100mm) and >40mm in the knee to be treated, partially responsive to chronic doses of nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, or weak opioids (codeine and tramadol);
  5. Ability to understand and provide signed consent through the Form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. History of /allergy to hyaluronic acid (HA) or other of the IP or product;
  2. Pregnant or breastfeeding women;
  3. Women at menace who do not agree to use acceptable methods (oral contraceptive, injectable contraceptive, IUD, hormonal implant, barrier methods, sexual abstinence, hormone transdermal patch and tubal ligation); except those who are surgically sterile (bilateral oophorectomy or hysterectomy);
  4. Emotional problems or any situation that, at the Investigator's discretion, places the safety of subjects at risk;
  5. Application of visco-supplementation to the knee less than four months prior to randomization;
  6. IA injection less than 4 months prior to randomization and/or schedule during the course of the study;
  7. Knee infection and/or inflammation (e.g., bursitis), skin infection at or around the IA injection;
  8. Swelling, redness, warmth, or other inflammatory signs in the knee in the investigator's description
  9. Knee injury or trauma;
  10. Patients with bleeding diathesis or on anticoagulant therapy;
  11. Major knee malformations or deformities that the investigator deems pertinent;
  12. Active cancer at the Investigator's discretion;
  13. Continuous or frequent use (use for more than 2 weeks in the last 2 months) of corticosteroids by any route of administration (oral, IM, IV)
  14. Concomitant use of chondroprotective drugs such as glucosamine, chondroitin, or collagen. These medications should not be introduced during the study, but if the patient is already taking them may be included, but the medication will not change.
  15. Need for the use of strong opioids (methadone, fentanyl, morphine, and oxycodone) for pain management;
  16. Participation in a clinical trial within the last twelve months prior to enrollment (CNS Resolution 251, dated 07 August 1997, item III, item J), unless the investigator believes that there may be a benefit to the patient.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    EVI-01 - low dose

    4 mL, one single EVI-01 intra-articular injection

    Device: EVI-01

  • Experimental
    EVI-01 - high dose

    6 mL, one single EVI-01 intra-articular injection

    Device: EVI-01

  • Active comparator
    Synvisc-One

    6 mL, one single intra-articular injection

    Device: Active comparator Synvisc-One

Interventions

  • DeviceEVI-01

    Single intra-articular injection of high molecular weight hyaluronic acid

  • DeviceActive comparator Synvisc-One

    Single intra-articular injection of active comparator Synvisc-One

07

What researchers measure

Primary outcomes

  1. Changes to the questionnaire WOMAC A (Western Ontario and McMaster Universities) Numeric 3.1

    Questionnaire WOMAC A (Western Ontario and McMaster Universities) numeric scale, version 3.1, total knee pain score (pain, stiffness and physical function assessment)

    Time frame: from baseline to 180 days after randomization

  2. Comparison of treatment-related Adverse Events in the three groups

    Incidence of treatment-emergent adverse events

    Time frame: from baseline to 180 days after randomization

Secondary outcomes

  1. Changes to the WOMAC (Western Ontario and McMaster Universities) Total Numeric 3.1 score

    WOMAC (Western Ontario and McMaster Universities) numeric scale, version 3.1 (pain, stiffness and physical function assessment)

    Time frame: from baseline to 180 days after randomization

  2. Changes to the WOMAC (Western Ontario and McMaster Universities) A score

    WOMAC (Western Ontario and McMaster Universities) A numeric scale, version 3.1, total knee pain score (pain, stiffness and physical function assessment)

    Time frame: from Day 1 to Day 7 after randomization

  3. Response to the Euro Quality of Life Questionnaire

    Euro Quality of Life Questionnaire version EQ-5D-5L

    Time frame: from baseline to 180 days after randomization

  4. Response rate, according to OMERACT-OARSI2 international criteria

    OMERACT-OARSI2 (Outcome Measures in Rheumatology Committee - Osteoarthritis Research Society International)

    Time frame: from baseline to Days 28, 90 and 180 after randomization

08

Study locations

2 sites
  • A2Z Clinical
    Valinhos, São Paulo, Brazil
  • Ortocity
    São Paulo, Brazil
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Oct 2025, 21 months.

Of 139 industry-sponsored interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's 21 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2022
First posted
Apr 20, 2022
StartActual
Jan 17, 2024
Primary completionActual
Oct 29, 2025
CompletionActual
Oct 29, 2025
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05337540
Lead sponsor
Aptissen SA
Collaborators
Azidus Brasil
Responsible party
Sponsor
First posted
Apr 20, 2022
Start date
Jan 17, 2024
Primary completion
Oct 29, 2025
Completion
Oct 29, 2025
Last update
Dec 8, 2025

Study contacts

Guilherme Gracitelli, MD
principal investigator · C.E.P.O.T. - Centro de Estudos e Pesquisas em Ortopedia e Traumatologia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion